Home ›
Entities
› academia
› An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Research article (Health Policy, 2018) · cited 27× · AI/ML
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Summary
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? is a scholarly article[1].
Key Facts
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?'s instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?. Retrieved May 24, 2026, from https://4ort.xyz/entity/an-exploratory-case-study-of-the-impact-of-expanding-cost-effectiveness-analysis-for-second-line-nivolumab-for-patients-
MLA“An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/an-exploratory-case-study-of-the-impact-of-expanding-cost-effectiveness-analysis-for-second-line-nivolumab-for-patients-.
BibTeX@misc{4ortxyz_an-exploratory-case-study-of-the-impact-of-expanding-cost-effectiveness-analysis-for-second-line-nivolumab-for-patients-_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?}}, year = {2026}, url = {https://4ort.xyz/entity/an-exploratory-case-study-of-the-impact-of-expanding-cost-effectiveness-analysis-for-second-line-nivolumab-for-patients-}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? — https://4ort.xyz/entity/an-exploratory-case-study-of-the-impact-of-expanding-cost-effectiveness-analysis-for-second-line-nivolumab-for-patients- (retrieved 2026-05-24)
